who medicines strategy - libdoc.who.int - World Health Organization
who medicines strategy - libdoc.who.int - World Health Organization who medicines strategy - libdoc.who.int - World Health Organization
WHO MEDICINES STRATEGY 2004-2007 | 132REQUEST FOR SUPPORT FROM COUNTRYIf WHO has not been active in pharmaceuticals in a country before or fora long period of timeREQUEST FOR SUPPORT FROMCOUNTRIES OR REGIONSTYPE ASITUATION ANALYSIS> Determine priority needs and what further support would be mostappropriate> Financed primarily from unspecified fundsTYPE BSPECIFIC TECHNICALSUPPORTTYPE CCOMPREHENSIVEPROGRAMME SUPPORTTYPE ICINTERCOUNTRY PROGRAMMES> Timely interventions usuallyfocused on a subset of thefollowing areas: policy, access,quality safetyy and efficacy,rational use> Financed primarily fromunspecificed funds*i.e. funds for which the donor hasnot specified a particular purposeor use.**i.e. funds for which the donor hasspecified a particular purpose or use.> Ministry of Health/WHOimplementation plan coveringmost or all of the followingareas: policy, access, quality,safety and efficacy, rational use> Financed primarily fromspecified funds**> Time frames may cover two ormore biennia> Usually necessitates full-timepharmaceutical adviser incountry> May involve drug supply> Involves two or more countries,frequently from the same region> Financed primarily from unspecifiedfunds*> Usually focused on a subset of thefollowing areas: policy, access,quality, safety and efficacy, rationaluse
IMPLEMENTING THE STRATEGY | 133Working with countries – supporting andenabling national resources/capacityWorking with countries on policy and technicalissues has always been and continues to bethe highest priority for WHO in the field ofmedicines. It is essential that countries` needs andexperiences are at the core of all WHO’s work inpharmaceuticals.WHO support in medicines is demand driven. Itcan be classified into four main types, sometimesused in combination: situation analysis, specifictechnical support, comprehensive programmesupport, and intercountry programmes. In2002, WHO provided direct support in thepharmaceutical sector to 113 countries.Twenty-two countries received comprehensiveprogramme support, 85 received specifictechnical support, and WHO supported sixcountries in situational analyses 70 .Country work is also a fundamental resource forWHO. Only by undertaking such work can theOrganization develop its evidence and knowledgebase and continue to maintain its position as theleading UN technical agency on public healthissues.WHO working together – coordination,communication and collaborationWHO country support in medicines benefitsfrom effective coordination, collaboration, andcommunication between EDM teams and WHOheadquarters, regional offices, and country officesand between WHO and its partners. Workingtogether enables a unified vision for the futureand a common strategy to reach it. WHO’sguiding principles for country support are given inFigure 28.Strengthening WHO regional andcountry capacityTo improve its effectiveness at country level,WHO is implementing a strategy to strengthen itsregional and country offices. An important part ofdecentralization and strengthening WHO capacityhas been the appointment of regional and issuefocal points at headquarters, an increase in thenumber of staff in regional offices, the recruitmentof Medicines Advisers in selected country offices,and efforts to strengthen partnerships with healthcare providers, CSOs, consumers, donors, andother international agencies.Each regional office has an essential medicines
- Page 94 and 95: WHO MEDICINES STRATEGY 2004-2007 |
- Page 96 and 97: WHO MEDICINES STRATEGY 2004-2007 |
- Page 98 and 99: WHO MEDICINES STRATEGY 2004-2007 |
- Page 100 and 101: WHO MEDICINES STRATEGY 2004-2007 |
- Page 102 and 103: WHO MEDICINES STRATEGY 2004-2007 |
- Page 104 and 105: WHO MEDICINES STRATEGY 2004-2007 |
- Page 106 and 107: WHO MEDICINES STRATEGY 2004-2007 |
- Page 108 and 109: WHO MEDICINES STRATEGY 2004-2007 |
- Page 110 and 111: WHO MEDICINES STRATEGY 2004-2007 |
- Page 112 and 113: WHO MEDICINES STRATEGY 2004-2007 |
- Page 114 and 115: WHO MEDICINES STRATEGY 2004-2007 |
- Page 116 and 117: WHO MEDICINES STRATEGY 2004-2007 |
- Page 118 and 119: WHO MEDICINES STRATEGY 2004-2007 |
- Page 120 and 121: WHO MEDICINES STRATEGY 2004-2007 |
- Page 122 and 123: WHO MEDICINES STRATEGY 2004-2007 |
- Page 124 and 125: WHO MEDICINES STRATEGY 2004-2007 |
- Page 126 and 127: WHO MEDICINES STRATEGY 2004-2007 |
- Page 128 and 129: WHO MEDICINES STRATEGY 2004-2007 |
- Page 130 and 131: WHO MEDICINES STRATEGY 2004-2007 |
- Page 132 and 133: WHO MEDICINES STRATEGY 2004-2007 |
- Page 134 and 135: WHO MEDICINES STRATEGY 2004-2007 |
- Page 136 and 137: WHO MEDICINES STRATEGY 2004-2007 |
- Page 138 and 139: WHO MEDICINES STRATEGY 2004-2007 |
- Page 140 and 141: WHO MEDICINES STRATEGY 2004-2007 |
- Page 142 and 143: WHO MEDICINES STRATEGY 2004-2007 |
- Page 146 and 147: WHO MEDICINES STRATEGY 2004-2007 |
- Page 148 and 149: WHO MEDICINES STRATEGY 2004-2007 |
- Page 150 and 151: WHO MEDICINES STRATEGY 2004-2007 |
- Page 152 and 153: WHO MEDICINES STRATEGY 2004-2007 |
- Page 154 and 155: WHO MEDICINES STRATEGY 2004-2007 |
- Page 157 and 158: REFERENCES
- Page 159 and 160: REFERENCES | 1471Annual report 2000
- Page 161 and 162: REFERENCES | 14912 th Model List of
IMPLEMENTING THE STRATEGY | 133Working with countries – supporting andenabling national resources/capacityWorking with countries on policy and technicalissues has always been and continues to bethe highest priority for WHO in the field of<strong>medicines</strong>. It is essential that countries` needs andexperiences are at the core of all WHO’s work inpharmaceuticals.WHO support in <strong>medicines</strong> is demand driven. Itcan be classified <strong>int</strong>o four main types, sometimesused in combination: situation analysis, specifictechnical support, comprehensive programmesupport, and <strong>int</strong>ercountry programmes. In2002, WHO provided direct support in thepharmaceutical sector to 113 countries.Twenty-two countries received comprehensiveprogramme support, 85 received specifictechnical support, and WHO supported sixcountries in situational analyses 70 .Country work is also a fundamental resource forWHO. Only by undertaking such work can the<strong>Organization</strong> develop its evidence and knowledgebase and continue to ma<strong>int</strong>ain its position as theleading UN technical agency on public healthissues.WHO working together – coordination,communication and collaborationWHO country support in <strong>medicines</strong> benefitsfrom effective coordination, collaboration, andcommunication between EDM teams and WHOheadquarters, regional offices, and country officesand between WHO and its partners. Workingtogether enables a unified vision for the futureand a common <strong>strategy</strong> to reach it. WHO’sguiding principles for country support are given inFigure 28.Strengthening WHO regional andcountry capacityTo improve its effectiveness at country level,WHO is implementing a <strong>strategy</strong> to strengthen itsregional and country offices. An important part ofdecentralization and strengthening WHO capacityhas been the appo<strong>int</strong>ment of regional and issuefocal po<strong>int</strong>s at headquarters, an increase in thenumber of staff in regional offices, the recruitmentof Medicines Advisers in selected country offices,and efforts to strengthen partnerships with healthcare providers, CSOs, consumers, donors, andother <strong>int</strong>ernational agencies.Each regional office has an essential <strong>medicines</strong>
Change language